<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41905">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962324</url>
  </required_header>
  <id_info>
    <org_study_id>PARAPLY-1</org_study_id>
    <nct_id>NCT01962324</nct_id>
  </id_info>
  <brief_title>Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer</brief_title>
  <acronym>PARAPLY-1</acronym>
  <official_title>Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm phase 2 study to study the outcome of dose-escalation with simultaneous
      integrated boost to intraprostatic lesion and positive lymph nodes. Prostate cancer patients
      with high risk of lymph node metastasis or oligo positive nodes in true pelvic area can be
      included. The boost volumes will be outlined by usin PET-CT and MRI data. Our hypothesis is
      that we will have fewer relapses in this very high risk patient group compared to matched
      historical controls with acceptable side effects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PSA progression free survival</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSA progression defined according to American Society for Therapeutic Radiology and Oncology (ASTRO) Phoenix definition: nadir PSA + 2 ng/mL (on three consecutive measurements with at least one month between each)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>0,6,12,36,60 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Questionnaires distributed to patients at these time intervals</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Lymphatic Metastasis</condition>
  <arm_group>
    <arm_group_label>SIB Dose-Escalation radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous integrated boost to intraprostatatic tumor and lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB Dose-Escalation Radiotherapy</intervention_name>
    <arm_group_label>SIB Dose-Escalation radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high risk prostate cancer with a risk of lymphatic spread
             &gt;15% according to the MSKCC nomogram (1)
             http://nomograms.mskcc.org/Prostate/PreTreatment.aspx

          -  Written informed consent

          -  &gt; 18 years

          -  Fiducial gold markers implanted in the prostate (min 3)

        Exclusion Criteria:

          -  • Non MR-safe implants or other contraindication to MRI

               -  WHO PS&gt;1

               -  Previous pelvic irradiation

               -  TURP within 6 months

               -  IPSS &gt;19

               -  Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the
                  pelvis

               -  Creatinin clearance &lt; 30ml/min according to
                  http://www.fass.se/LIF/produktfakta/kreatinin.jsp
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
    <phone>+46 90 785 0000</phone>
    <email>camilla.thellenberg@onkologi.umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders Widmark, Professor</last_name>
    <phone>+46 90 +785 0000</phone>
    <email>anders.widmark@onkologi.umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umeå University, Cancercenter</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla§ Thellenberg KArlsson, MD, PhD</last_name>
      <phone>+46 90 785 0000</phone>
      <email>camilla.thellenberg@onkologi.umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Anders Widmark, Professor</last_name>
      <phone>+46 90 785 00 00</phone>
      <email>anders.widmark@onkologi.umu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 11, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Camilla Thellenberg Karlsson</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiotherapy, dose-escalation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
